Skip to main content
PLOS One logoLink to PLOS One
. 2024 Dec 31;19(12):e0309797. doi: 10.1371/journal.pone.0309797

LC-MS profiling and cytotoxic activity of Angiopteris helferiana against HepG2 cell line: Molecular insight to investigate anticancer agent

Bipindra Pandey 1, Shankar Thapa 1,*, Mahalakshmi Suresha Biradar 2, Bhoopendra Singh 3, Jaya Bahadur Ghale 4, Pramod Kharel 5, Prabhat Kumar Jha 6, Ram Kishor Yadav 6, Sujan Dawadi 7, Poojashree V 8
Editor: Ghulam Mustafa9
PMCID: PMC11687663  PMID: 39739862

Abstract

Liver cancer is one of the most prevalent malignant diseases in humans and the second leading cause of cancer-related mortality globally. Angiopteris helferiana was mentioned as a possible anticancer herb according to ethnomedicinal applications. However, the molecular docking and chemical profiling of the bioactive phytoconstituents accountable for the reported anticancer action still require research. The present study aims the phytochemical profiling and bioactivity evaluation of A. helferiana. The study design with in-vitro and in-silico technique of the LC-MS followed by a study of the ligand–protein interaction using the molecular docking method, and investigates the cytotoxic activity by MTT assay of A. helferiana bioactive compounds on HepG2 cell lines. LC-MS results detected seventeen phytoconstituents in A. helferiana extract belonging to variable chemical classes with most prevailing compounds such as Vicenin 1, Schafroside, Violanthin, Coumarin, Quercetin, Angiopterioside, and Corosolic acid. The finding concluded that Quercetin showed significant binding energy of -8.8 kcal/mol and then Schafroside also possesses the binding energy of -8.1 kcal/mol against the human PPAR-δ receptor (PDBID: 1I7G). The extract showed the moderate cytotoxic activity having IC50 value of 236.93 μg/mL. Our finding suggests that these bioactive compounds could be developed as promising anticancer agent, but further in-vivo study require to validate the finding along with isolation of individual phytoconstituents.

1. Introduction

Liver is vital organ which is most susceptible to harm from exposure to xenobiotics (drugs, alcohol, illicit drugs, environmental toxins, and others), leading to a very high incidence of liver diseases [1]. Worldwide and in Nepal, the death rates from cancer, cirrhosis, fatty liver, and chronic hepatitis are high. Liver cancer is one of the most common malignant cancers in humans and the second largest cause of cancer-related death worldwide. It is a serious issue, particularly in less developed countries. An estimated 50% of medications were obtained through the use of herbal products. Ultimately, cancerous cells cause damage to the tissues and cause damaged to sudden cell divisions that multiply in healthy body cells, organ dysfunction and even death may be the result of these injured tissues [2, 3].

The main sources of new plant-based natural products with potential anticancer properties are their ethnomedical applications. Natural products are the main source of potent anticancer medications with innovative structures and distinct modes of action for the treatment of different types of cancer. Many plant-derived phytoconstituents have been used to treat hepatocellular carcinoma (HCC), including saponins, alkaloids, flavonoids, terpenes, and polysaccharides [4, 5]. Every segment of the global population is impacted by HCC. With the second highest death rate among all cancers, HCC is ranks as the fifth universal cancer among other cancers [6]. Annually, liver cancer is predicted to affect over a million people globally by 2025, making it a major global health concern. Ninety percent of cases of liver cancer are HCC, which has a high morbidity and mortality rate [7, 8].

Recent technological developments have made tandem analytical techniques such as; Liquid chromatography-mass spectroscopy (LC-MS), LC-MS/MS, Liquid chromatography-nuclear magnetic resonance (LC-NMR), and LC-NMR/MS are available [9, 10]. A potent method for characterizing target phytoconstituents in intricate plant extracts is tandem mass spectrometry (MS/MS). When compared to other dereplication techniques due to high sensitivity, selectivity, and quick screening capabilities via the online identification of secondary metabolites in plant extracts, the LC-MS/MS technique’s is used [11]. Furthermore, the amount of time, money, and effort needed to screen natural products for biological activity has decreased significantly thanks to developments in computational biology [12, 13]. Nowadays, a lot of researcher use molecular docking to predict the binding affinity and mode of a drug-like molecule into the receptor’s active site [14]. Virtual screening of a vast number of natural and synthetic compounds for activity against a variety of targets could save time, effort, and provide a quick expectation for the most promising anticancer candidates [15].

Angiopteris helferiana (A. helferiana) C. Presl is a large fleshy fern that is a member of the Marattiaceae family and can be found in moist forests in Southeast Asia, China, Nepal, India, and Sri Lanka at elevations between 900 to 1400 meters. In Nepal, the rhizome of A. helferiana is traditionally used to treat fatigue, muscle and bone pain [16]. The rhizome of this plant is also reportedly used in the Konkan region of Maharashtra, India, to treat scabies. In Bangladesh, the rhizome of A. helferiana was used in dysentery, infections, scabies, and muscular aches. Similarly, A. helferiana leaf is used ethnomedicinally to treat bloating and hair loss by making its topical powder and oral soup [17].

Prior research on the light yellow-colored rhizome of A. helfiarana revealed biological activity including hepatoprotective activity, anti-inflammatory, anti-obesity, and antidiabetic properties [18]. Additionally, Angiopteroside and (−)-epi-Osmundalactone, two lactones, were also isolated from the same cultivars [16]. The different species of Angiopteris show significant anticancer activity [19]. More precisely, S. Sara and R. Ruby explored the antiproliferative effect of Angiopteris evecta against cultured HT-29 colon cancer cells in their book chapter [20]. Similarly, S. Nur et al. [21], reported the significant cytotoxic effect of Angiopteris ferox against different three cancer cell line. A. Aisyah et al., reported cytotoxic effect of methanolic fraction of Angiopteris ferox against pulmonary HTB cell line with an IC50 grade of 78.96 μg/mL [22]. These data make us curious to explore the cytotoxic activity of A. helferiana against hepatocellular carcinoma (HepG2 cell line). Moreover, to date, there have been no reports on the cytotoxic activity, LC-MS/MS profiling, and in-silico studies from the local cultivars (Rato Gai-khurey) of A. helferiana. In this study, Liquid chromatography-mass spectroscopy (LC-MS) profiling, Fourier transform infrared spectroscopy (FTIR) analysis, cytotoxic activities and computational studies of bioactive compounds from A. helferiana were carried out, which might lead to the potential management of hepatocellular carcinoma.

2. Results and discussion

2.1. FT-IR spectra interpretation

The functional groups of the extract of A. Helferiana were determined using FT-IR spectroscopy. The spectrum shows the characteristic absorption peak at the range of 3500 to 3250 cm-1. The peak was broad having medium intensity which indicate the presence of hydrogen bonded alcoholic or phenolic group in the extract (Fig 1). Moreover, the presence of sharp peak at 2927cm-1 confirms the presence of aliphatic C-H group. A medium sharp absorption peak was observed at 2362 cm-1 indicates the presence of C≡N group. It is noteworthy to mention that, the presence of carbonyl group (C = O, stretching) is supported by the strong absorption peak in the range of 1703 to 1627 cm-1. Furthermore, a strong-intensity absorption peak at 1054 cm-1 confirms the presence of ester (C-O, stretching) functional group. Other noticeable peaks are presents around 1392 cm-1and 1269 cm-1. A peak at 1392 cm⁻1 was likely due to the C-H bending vibrations from methyl groups or potentially symmetric stretching from a nitro group. Similarly, a peak at 1269 cm⁻1 was likely due to the C-O stretching vibrations from an ether group or deformation from a nitro group. The bending and stretching vibration from 900 cm-1 to 500 cm-1 represents the finger printing region of A. helferiana extract. Finger print region is the distinct characteristic region for the sample which is unique for each compound [23].

Fig 1. FT-IR spectra of Angiopteris helferiana.

Fig 1

2.2. LC-MS profiling

Untargeted LC-MS analysis was conducted to examine and provisionally identify the isolated metabolites. The LC-MS analysis of an ethanolic extract detected several substances. The secondary metabolites were identified through the use of LC retention time, molecular mass and high-resolution mass spectra analysis in the extracts (Fig 2). We detected the peaks in LC-MS chromatograms by utilizing mass spectra m/z databases including Mass Bank of Europe (https://massbank.eu/MassBank/) and National Library of Medicine (https://www.nlm.nih.gov/), as well as relevant literature [2427]. The discovered peaks are labelled as tentative due to the presence of natural products in isomeric forms, including isomerization of aglycones (e.g. flavones and isoflavones), or as isobaric compounds with the same molecular weight but distinct elemental composition [28].

Fig 2. LC-MS spectra of Angiopteris helferiana extract.

Fig 2

A total of 17 phytoconstituents were found in the extracts, consisting of phenolic acids, flavonoids, and polyphenols (Figs 2S to 15S in S1 File). We also detected minor number of amino acids, ascorbic acid, and trace element but excluded from the analysis. The precursor ions at m/z 564 and 578 identified the Flavonoid glycoside clusters as Vicenin 1, Isoschaftoside, Schafroside, and Violanthin, respectively. The flavonoids were identified at m/z 146 and 302, corresponding to clusters of Coumarin and Quercetin, respectively. Additionally, from precursor ions at m/z 290 and 472 suggests natural product, indicating the presence of Angiopteroside and Corosolic acid (Table 1).

Table 1. LC-MS data-positive ion mode for tentative compounds identification in plant extract.

SN RT Formula MS ion (m/z)
[M+H]
MS/MS (m/z)
fragment ions
Tentative
Identification
Area
(%)
Chemical
classification
1 0.602 C7H5FN2 136 122, 117, 100, 57 4-Fluro-1H-indazole 20.531 Heterocyclic compound
2. 1.853 C7H6O4 180 128, 113, 89, 57 Acetyl salicylic acid 4.396 Organic aromatic compound
3. 2.20 C26H28O14 564 437, 324, 301, 205, 150, 149, 57 Vicenin 1, Isoschaftoside, Schafroside 0.560 Flavonoid glycoside
4. 2.55 C27H30O12 578 463, 419, 375, 149, 143, 122, 57 Violanthin 1.130 Flavonoid
5. 2.77 C20H12O5F2 412 301, 283,282, 265, 177, 149, 97 Oregon green 0.458 Organic aromatic compound
6. 2.87 C13H18O7 290 238, 211, 122, 117, 57 Angiopteroside, Osmundalin 3.786 Glycoside
7. 3.02 C20H22O2N2 324 207, 290, 217, 195, 128, 113, 89 Quinine 7.178 Alkaloid
8. 3.30 C27H30O15 564 477, 383, 307, 237, 216, 118, 117, 115 Vicenin 2, Vicenin 3 0.374 Flavonoid glycoside
9. 4.35 C29H45O4 472 404, 347, 299, 238, 211, 122, 117, 57 Corosolic acid 0.422 Pentacyclic triterpene
10. 4.67 C9H6O2 146 149, 122,118, 101, 100, 57, 90 Coumarin 14.823 Coumarin
11. 4.86 C15H12O6 302 242, 175, 113, 69 Quercetin 1.038 Flavonoid
12. 5.00 C7H10O2 100 89, 70, 57 Osmundlactone 11.546 Heterocyclic compound
13. 5.60 C27H30O14 578 418, 395, 339, 311, 249, 133, 113, 69 Isoviolanthin 0.908 Flavonoid glycoside

Note: RT = Retention time; SN = Serial number.

2.3. Protein validation

The PROCHECK service facilitates in assessing the three-dimensional geometry of protein structures by categorizing residues into different colours based on their areas: red (preferred), yellow (additionally allowed), pale yellow (generously allowed), and white (disallowed) [29], as illustrated in Fig 3. Ramachandran plots for all residue types are displayed in Fig 16S in S1 File. Human PPAR-δ protein contains 259 residues, with 217 (92.3%) of them located in the most liked area (A, B, L). Approximately 18 residues (7.7%) were found in the additional authorized regions (a, b, l, p). None of the residues located in generously allowed regions and residue in banned regions (Fig 3). Within the human PPAR-δ protein, 235 residues were non-proline and non-glycine. Proline and glycine residues are depicted as triangles, with 9 and 10 occurrences, respectively. Fig 16SB in S1 File displays the hydrophobicity map of the human PPAR-δ protein in the study. The amino acid residues are indicated in brackets, with those in poor conformations (score < -3.0) labelled. Shaded regions represent favorable conformations observed in163 structures analyzed at a resolution of 2.0Å or higher. The shading represents advantageous conformations identified from an examination of 163 structures with a resolution of 2.0Å or higher.

Fig 3. Ramachandran plot to validate the protein.

Fig 3

To be considered stable, a protein’s instability index must be less than 40 [30]. It was determined to be 34.08 in our instance, while the theoretical isoelectric constant was 5.86. It was discovered that the protein’s grand average hydropathy value (GRAVY) was -0.170. There are more details in the Table 2.

Table 2. Physiochemical properties of human PPAR-δ protein.

Physiochemical properties Human PPAR-δ (PDB ID: 1I7G)
Molecular Weight 52225.13
Molecular Formula C2303H3655N619O695S34
Total no. of atoms 7306
Theoretical PI 5.86
Aliphatic index 86.69
Instability index 54.08
GRAVY -0.170
+R (Arg + Lys) 52
-R (Asp + Glu) 61
Ext. coefficient /Abs 0.1% (= 1 g/l) 0.399

2.4. Molecular docking

Molecular docking study was conducted to predict the binding affinity and binding orientation of phytoconstituents of A. helferiana extract against human PPAR-δ receptor (PDBID: 1I7G). Molecular docking is a computational technique used in drug discovery and molecular biology to predict the preferred orientation of molecules [31] (phytoconstituents of A. helferiana extract) when bound to a target molecule (human PPAR-δ receptor). It involves simulating the interaction between the two molecules to predict the most energetically favorable binding pose [32]. Molecular docking is highly significant as it aids understanding the binding mechanisms between drugs and their target proteins, facilitating the design of novel therapeutic compounds [33]. By predicting the binding affinity and mode of interaction, molecular docking helps prioritize potential drug candidates, saving time and resources in the drug development process and contributing to the identification of new agent for various diseases [34].

The role of PPAR-δ in cancer is intricate and context-dependent. PPAR-δ, a nuclear receptor, plays a pivotal role in regulating various physiological processes, including lipid metabolism, inflammation, and cell proliferation [35]. Its involvement in cancer is characterized by both anti-tumorigenic and pro-tumorigenic effects, with outcomes varying based on tissue type and specific cellular contexts. Activating PPAR-δ has been associated with inhibiting cell proliferation and inducing apoptosis in certain instances, suggesting potential anti-tumorigenic effects [36, 37]. Additionally, its anti-inflammatory properties may indirectly hinder tumorigenesis by reducing chronic inflammation. On the other hand, PPAR-δ activation has been linked to pro-tumorigenic effects, such as promoting angiogenesis and influencing lipid metabolism [38].

Around 17 phytoconstituents of A. helferiana extract were identified by LC-MS screening and subjected for docking. Site specific docking was utilized as it gives space to the ligands molecules to bind at validated specific site [39]. The docking results were sorted for phytoconstituents with least binding energy, maximum hydrogen bonding and minimum bond length. The interactions were visualised in 2D and 3D format included nature of bonding, bond length (Å) and respective binding energy in kcal/mol. Most prominent common amino acid participate for the interaction were Cys275, Cys277, Val332, Thr279, Tyr334, Met220 and Ala333. The prominent molecular interaction includes; conventional hydrogen bond, pi-pi stacked, pi-alkyl, carbon-hydrogen bond, pi-loan pair and pi-pi T shaped bond. Moreover, conventional hydrogen bonding is prominent with most of the interaction which indicate the possibility of stable ligand-protein complex. All the phytoconstituents showed moderate to good binding affinity ranges from -5.2 to -8.6 kcal/mol (Table 3). We have compared the test results with the native co-crystal ligand (AZ242) which showed good binding affinity of -7.7 kcal/mol. From phytoconstituents side, Quercetin (B12) and Schaftoside (B7) showed best binding affinity of -8.8 and -8.1 kcal/mol, respectively (Table 3). These two phytoconstituents exhibited better binding affinity than the native co-crystal ligand. However, Osmundlactctone (B8) showed the least binding affinity of -5.1 kcal/mol (Table 3).

Table 3. Molecular insight, binding site amino acid, binding affinity of phytoconstituents of A. helferiana against human PPAR-δ receptor (PDBID: 1I7G).

SN Compound name (code) Binding site amino acid Nature of interaction Binding affinity (ΔG) RMSD value (in Å)
1. Violanthin (B1) Arg226, Asn326, Lys222, Glu369 Conventional hydrogen bond, Pi-Pi stacked, Pi-alkyl, Carbon-hydrogen bond, Pi-loan pair and Pi-pi T shaped bond -7.1 2.451
2. Vicenin 1 (B2) Cys (275, 276, Leu245, Glu282, Thr279, ala333, Val332 -7.8 2.988
3. Vicenin 2 (B3) Cys (275, 276), Val332, Thr279, Glu282 -7.6 1.826
4. Vicenin 3 (B4) Cys (275, 276), Val332, Thr279, Glu282, Ala333 -7.7 2.806
5. Isoschaftoside (B5) Cys275, Val332, Leu254, Thr279, Ala333 -7.8 2.730
6. Isoviolanthin (B6) Pro357, Asp353, Glu439, Asp360 -7.1 2.874
7. Schaftoside (B7) Cys275, Val324, Glu282, Tyr334, Met220, Val332, Thr279, Met220 -8.1 2.727
8. Osmundlactctone (B8) Ile354, Cys276, Phe273, Tyr (314, 464), His440 -5.2 1.979
9. Angiopteroside (B9) Asn219, Met (220, 320), Phe218, Glu286, Tyr334 -7.6 2.627
10 Corosolic acid (B10) Arg388, Pro389, Tyr311, Thr438, Val437 -7.3 2.809
11. Coumarin (B11) Ser280, Gln277, Cys276, Val444, His440 -6.6 1.474
12. Quercetin (B12) Thr283, Glu286, Ser323, Tyr334, Met320 -8.8 2.165
13. Quinine (B13) Tyr (214, 334), Met (220, 320, 330), Phe218, Leu321 -7.6 2.511
14. Acetyl salicylic acid (B14) Met220, Val324 -6.0 1.740
15. 4-fluro-1H-indazole (B15) Ser280, Tyr314 -6.9 0.987
16. Oregon green (B16) Pro389, Arg434, Met467, Glu315, Val437, Tyr311, Arg388 -7.3 2.582
17. Osmundalin (B17) Glu286, Asn221, Asp372, Ser323 -7.4 2.565
18. Co-crystal ligand (AZ 242) Cys275, Thr279, Ala334, Ile317, Leu321, Val332 -7.7

Quercetin (B12) and Schaftoside (B7) both formed three conventional hydrogen bonds with Thr283, Glu286, Ser323 and Cys275, Thr279, Glu282, respectively (Figs 4 and 5). Quercetin (B12) had a lower binding energy compared to the co-crystal, indicating that it has a stronger affinity for the target than the co-crystal native ligand (Fig 6). Schaftoside (B7) had a shortened bond length of less than 2.5 Å, particularly for conventional hydrogen bonds, which enhances stability. Quercetin (B12) had a lower binding energy (better binding affinity) but showed a greater bond length between interacting amino acids and functional groups (more than 2.5 Å) compared to Schaftoside (B7). Increased bond distances could result in an unstable protein-ligand combination. Although the binding affinity of Quercetin (B12) was reported excellence but its stability issue, Schaftoside (B7) was consider best phytoconstituent to recommend for further investigation. Therefore, we recommend Schaftoside (B7) as a suitable candidate for more research. The 2D molecular interaction of other phytoconstituents is given in Figs 17S to 27S in S1 File.

Fig 4. 2D and 3D molecular interaction of Schaftoside (B7) against PPAR-δ (PDBID: 1I7G).

Fig 4

Fig 5. 2D and 3D molecular interaction of Quercetin (B12) against PPAR-δ (PDBID: 1I7G).

Fig 5

Fig 6. 2D and 3D interaction of co-crystal native ligand (Az 242) against PPAR-δ (PDBID: 1I7G).

Fig 6

2.5. ADME properties

The ADMETlab 2.0 server was utilized to investigate the ADME characteristics of 17 phytoconstituents. The phytoconstituents exhibited in the range of high to low gastrointestinal absorption (GIA), with probability score of 0.1–1 (symbol—and +++) [40]. Phytoconstituents B8 and B10-B16 belongs to the category 0 which indicates the human intestinal absorption (HIA) greater or equal to 30%. Remaining 9 phytoconstituents (B1-B7, B9 and B17) showed the HIA value less than 30% belonging to the category 1 (Table 4). The concentration of a substance in the nonpolar phase divided by its concentration in the aqueous phase at equilibrium is known as the partition coefficient (P). The LogP value is obtained by taking the logarithm of this ratio. LogP, or the logarithm of the partition coefficient, is a metric utilized in drug development to evaluate the lipophilicity or hydrophobicity of a substance. The compound’s partitioning tendency between an aqueous phase (often octanol) and a nonpolar phase is quantified [41]. Log of the octanal/water partition coefficient indicates that most of phytoconstituents don’t align with the optimal reference value of 0 to 3. However, the compound having high binding affinity (B12) showed the optimal LogP value of 2.15. Only Corosolic acid (B10) was insoluble (-4.53) in water. Remaining phytoconstituents were sparingly (-2 to -4) to freely soluble (0 to -2) in water. All these three parameters determine the absorption of phytoconstituents through gastrointestinal tract. All the phytoconstituents can distribute easily into the body compartment as all the phytoconstituents showed the optimal volume of distribution (VD) value (0.04–20 L/kg). The volume of VD determines the half-life and dosing frequency of the drug. If a drug has high VD, more of the drug is distributed in tissue than plasma. Metabolism of drugs is a complex biotransformation process, where drug molecules are get converted into their metabolites by various metabolizing enzymes [42]. The data provided in the table predicts whether the compound is likely to be metabolized by P450 or not. Most of the phytoconstituents did not inhibit the CYPA2 enzyme except B11, B12, and B15. Phytoconstituents B8, B11, B12 and B15 had moderate elimination rate (5–15 mL/min./kg) whereas remaining phytoconstituents has low renal clearance (less than 5 mL/min./kg). The predicted half-life (T1/2) of all the phytoconstituents was low (less than 3 hours) (Table 4).

Table 4. ADME properties of phytoconstituents.

Com. code Absorption Distribution Metabolism Elimination
LogP LogS HIA VD CYPA2 inh. CL T1/2
B1 0.28 -2.29 +++ 0.72 --- 1.35 0.475
B2 -0.05 -2.39 +++ 0.74 --- 1.23 0.55
B3 -0.33 -1.60 +++ 0.69 --- 1.25 0.64
B4 -0.33 -1.60 +++ 0.69 --- 1.25 0.64
B5 -0.06 -2.62 +++ 0.75 --- 0.75 1.26
B6 0.37 -2.17 +++ 0.75 --- 1.39 0.51
B7 -0.24 -2.10 +++ 0.79 --- 1.28 0.55
B8 0.20 0.50 --- 0.85 --- 5.50 0.84
B9 -1.05 -0.37 ++ 0.51 --- 1.73 0.84
B10 5.54 -4.53 --- 0.59 --- 2.12 0.12
B11 1.67 -2.01 --- 0.83 +++ 10.58 0.72
B12 2.15 -3.67 --- 0.57 +++ 8.28 0.92
B13 2.21 -2.63 --- 2.19 - 1.81 0.57
B14 1.23 -1.65 --- 0.23 --- 2.73 0.91
B15 2.01 -2.43 --- 1.64 +++ 9.95 0.38
B16 4.00 -3.77 --- 0.70 --- 0.91 0.57
B17 -1.71 -0.39 ++ 0.47 --- 1.63 0.64

2.6. Drug likeliness properties

The web server ADMETlab 2.0 was utilized to assess drug likeliness attributes based on Lipinski’s Parameter. The drug likeliness was assessed based on 2D molecular descriptors such as molecular weight (MW), hydrogen bond donor (HBD) count, hydrogen bond acceptor (HBA) count, rotatable bond (RB), Log P value, and molecular surface area (MSA). Lipinski’s Rule states that “for a compound to have good oral bioavailability, it should have a molecular weight of less than 500 Da, fewer than 10 hydrogen bond acceptors, fewer than 5 hydrogen bond donors, and an octanol/water partition coefficient of less than 5” [43]. Topological polar surface area (TPSA) is an acronym for topological polar surface area, a molecular descriptor utilized in drug design to evaluate the molecular size and complexity of a substance. It offers statistics on the molecule’s accessible surface area based on the quantity and variety of atoms it contains. The TPSA value serves as a parameter in drug-likeness assessments. Distinguishing between drug-like compounds and larger, more complex molecules with higher molecular weight and structural complexity can provide hurdles in development and optimization [44].

CaCO2 permeability plays an important role for drug absorption. The phytoconstituents B8, B11, B13, B15 and B16 showed the optimal CaCO2 permeability value (higher than −5.15 cm/s), but remaining 12 phytoconstituents showed a value lower than the optimal range (Table 5). Along with other phytoconstituents (B1-B7 and B11), Schaftoside (B7) violate the Lipinski’s rule of five whereas, Quercetin (B12) obey the rule. Furthermore, phytoconstituents B8, B9, B10, B13, B14, B15, B16, and B17 also obeyed the rule (Table 5). All the parameters are in favour towards the Quercetin (B12) to choose as best anti-cancer agent. But the molecular docking report suggest that, the unstable nature of Quercetin (B12) binding against receptor hinder the therapeutic efficacy of drug. Therefore, we consider Schaftoside (B7) could be the potential candidate as anti-cancer agent. Schaftoside (B7), part of phytoconstituent of plant A. helferiana, has demonstrated promising drug potential despite violating Lipinski’s Rule of 5. With a molecular weight of 564.15 Da, a CaCO2 permeability score of -6.37, and a TPSA of 250.97, Schaftoside (B7) exceeds the preferred limits for several key drug-likeliness parameters. Additionally, it possesses 14 hydrogen bond acceptors, 10 hydrogen bond donors, and 4 rotatable bonds, all contributing to its multiple Lipinski’s rule violations. However, the standout feature of Schaftoside (B7) is its impressive molecular docking score of -8.1 kcal/mol, indicative of a strong binding affinity to its target protein. Most importantly the Schaftoside (B7)-receptor (PPAR-δ) complex is stable. This significant binding affinity and stable ligand-receptor complex suggests a high potential for pharmacological efficacy. While the compound’s high TPSA and numerous hydrogen bond donors and acceptors may hinder its permeability and bioavailability, these characteristics also suggest a potential for strong and specific interactions with the target, which could enhance its therapeutic specificity and effectiveness.

Table 5. Drug likeliness properties of phytoconstituents.

Com. code MW CaCO2 per. TPSA HBA HBD nRB LR 5
B1 578.16 -6.40 250.97 14 10 4 Violation
B2 564.15 -6.38 250.97 14 10 4 Violation
B3 594.16 -6.42 271.20 15 11 5 Violation
B4 594.16 -6.42 271.20 15 11 5 Violation
B5 564.15 -6.37 250.97 14 10 4 Violation
B6 578.16 -6.39 250.97 14 10 4 Violation
B7 564.15 -6.37 250.97 14 10 4 Violation
B8 100.00 -4.68 46.53 3 1 0 Obey
B9 290.10 -5.69 125.68 8 4 3 Obey
B10 472.36 -5.44 77.76 4 3 1 Obey
B11 146.04 -4.58 30.21 2 0 0 Violation
B12 302.04 -5.20 131.36 7 5 1 Obey
B13 324.18 -4.97 45.59 4 1 4 Obey
B14 180.04 -5.06 63.60 4 1 3 Obey
B15 136.04 -4.38 28.68 2 1 0 Obey
B16 412.04 -4.94 125.04 7 3 3 Obey
B17 290.10 -5.74 125.68 8 4 3 Obey

Despite the challenges posed by its physicochemical properties, the strong binding affinity of Schaftoside (B7) underscores its potential as a therapeutic agent. Many successful drugs have been developed that violate Lipinski’s rules but are effective due to their potent biological activity [4547]. Therefore, Schaftoside (B7) merits further investigation and optimization. Strategies to improve its bioavailability and permeability, such as chemical modifications or advanced drug delivery systems, could unlock its potential. The promising binding affinity demonstrated by Schaftoside (B7) highlights the need for continued research to harness its therapeutic capabilities.

2.7. Analysis of passive membrane permeability and translocation pathways

The passive membrane permeability of pharmaceuticals can be determined experimentally using the PAMPA, which involves quantifying the substances that have moved across a flat artificial membrane from donor to acceptor wells [48]. Novel techniques have been created to track the entrance of pharmaceuticals into single-layered liposomes in real-time by utilizing fluorescent markers. The drug membrane permeability (P) is calculated as the ratio of the drug flow (J) through the membrane to the difference in drug concentrations between the donor (outside) and acceptor (inside) compartments, expressed as P = J/ΔC [49, 50].

The PerMM software was used to estimate the mean potential force profile (PMF) across the membrane, as shown in Figs 7 and 8, and determine the permeability coefficient across a dioleoyl-phosphatidylcholine (DOPC) bilayer membrane, as listed in Table 6, for the compounds under investigation (B7 and B12). This method allows for the prediction of important physicochemical parameters associated with how chemicals interact with the lipid bilayer. The PMF analysis provides insights into the energy landscape of compound translocation across the membrane, while the permeability coefficient data delivers statistical data on their diffusion through the lipid bilayer [51]. Evaluating the compounds’ potential application and efficiency in diverse biomedical and pharmaceutical contexts is made possible by these thorough examinations, which also greatly add to our understanding of the compounds’ behaviour at the molecular level. The two phytoconstituents continued to the selection for membrane permeability on the basis of their significance binding affinity. The results showed that both the phytoconstituents (B7 and B12) could penetrate the plasma membrane through passive diffusion. The energy transfer influences the membrane’s permeability to a substance. Energy transfer is the amount of energy needed to move through the plasma membrane, and this value varies based on the compound’s location in the lipid bilayer. Hydrophobic molecules exhibit the highest energy transfer values at the centre and the lowest at the ends of the lipid bilayer. Hydrophobic molecules have the lowest energy transfer at the center and the highest at the periphery [49].

Fig 7. Pathway of passive diffusion across the cell membrane for compound Schaftoside (B7).

Fig 7

Fig 8. Pathway of passive diffusion across the cell membrane for compound Quercetin (B12).

Fig 8

Table 6. Permeability predictions as calculated using the PerMM server.

SN Phytoconstituents Free energy of binding (DOPC)
1. Schaftoside (B7) -2.71 kcal/mol
2. Quercetin (B12) -2.00 kcal/mol

The result in (Figs 28S to 31S, Tables 3S and 4S in S1 File) reveals that both phytochemicals had negative energy profiles consistently across all depths of the graph, with a stable state detected near the membrane’s core. The chemicals analyzed have high ClogP values, indicating that they are likely to partition more into the hydrophobic inner area of the lipid bilayer rather than the lipid-water interface in the membrane. The energy minimum for both compounds is expected to be located at the point of contact with the initial lipid layer (about 2 nm). The binding free energy increases with the molecule’s lipophilicity. After passing through the initial lipid layer, a new energy barrier must be overcome before reaching the subsequent lipid layer. Given that the energy profiles resemble those found in the compounds (menthol carbonates) described by Mollazadeh et al. [52], it is plausible that a "flip-flop" motion takes place in these compounds, enabling faster movements between layers and potentially achieving higher concentrations on the cytoplasmic side. PerMM’s projected permeability coefficients confirm the preceding assumptions (Table 6).

2.8. HepG2 cell line study

The cytotoxic activity of A. helferiana extract (sample name Gai Khurey) was evaluated on HepG2 cell line by MTT assay. The IC50 stands for half-maximal inhibitory concentration, which is a measure of the potency of a substance in inhibiting a biological or biochemical function by 50%. In this case, the IC50 values are given in μg/mL, indicating the concentration at which each substance is able to inhibit the growth of HepG2 cells by 50% [53].This screening was conducted to validate the in-silico molecular docking results. A. helferiana extract exhibited an IC50 value of 236.93 μg/mL, indicating that a relatively large concentration is required to inhibit 50% of the HepG2 cells. This suggests that the extract has moderate to low cytotoxicity against this liver cancer cell line, highlighting its potential as an anticancer agent, though it is considerably less potent compared to established treatments (Table 7 and Fig 9). In contrast, 5-Fluorouracil demonstrated a significantly lower IC50 value of 5.0 μg/mL [54], indicating a strong cytotoxic effect and requiring only a small concentration to achieve 50% inhibition. Despite the higher IC50 of A. helferiana extract, its moderate cytotoxicity suggests the presence of bioactive compounds with potential anticancer properties, warranting further investigation.

Table 7. Anticancer activity of Angiopteris helferiana extract on HepG2 cell line by MTT assay.

SN Sample HepG2 cell lineIC50 in μg/mL
1. Angiopteris helferiana extract 236.93
2. 5- Fluorouracil 5.0 [54]

Note: “An extract is defined to be highly active if it has IC50 < 10 μg/ml, active when the IC50 is between 10 μg/ml and 100 μg/ml, moderately active if the IC50 is between 100μg/ml and 500 μg/ml, and low activity if the IC50 is ˃ 500 μg/ml” [55].

Fig 9. HepG2 cell line vs Angiopteris helferiana extract.

Fig 9

3. Conclusion

The current research provides the evidence of presence of 17 phytoconstituents such as Vicenin 1, Violanthin, Schafroside, Coumarin, Quercetin, Angiopteroside, Corosolic acid, etc in A. helferiana extract. It was reported the extract had a cytotoxic activity against HepG2 cell line by MTT assay. Therefore, we believe that these phytoconstituents may serve as a source for novel lead structures in the development of cancer-fighting agents. Furthermore, molecular docking, drug likeliness properties, and cell membrane permeability test revealed that the Quercetin (B12) had a high binding affinity for the target protein with best membrane permeability obeying the Lipinski’s rule of five to be a drug candidate. However, the instability of ligand-receptor complex hinders its potency as anti-cancer agents. Instead Schaftoside (B7) showed the best stability to binds with receptor and showed the significant potency. In conclusion, A. helferiana extract may be the effective therapeutic lead for anticancer drugs but it acquires further experimental validation.

4. Limitation of the study

We do not claim the precision and accuracy of interpretation of LC-MS data due to the unavailability of precise and accurate reference mass data. There is very limited research on LC-MS profiling for A. helferiana. Due to the lack of sophisticated lab, we were unable to isolate individual phytoconstituents from A. helferiana extract which may affected the accuracy of in-vitro result.

5. Materials and methods

5.1. Collection and authentication of plant

Fresh rhizomes of A. helfiarana were collected in May, 2023 from Vyas municipality, Tanahun district, Nepal (geographical coordinate = 27.989131, 84.287275, https://maps.app.goo.gl/xQ93UaMFqodA5ypZ8). Since the plant collection site was open to public, permission from the municipality was not required. The authenticity of the plant specimen (31/02/2080/Herbarium specimen No) was confirmed at the National Herbarium and Plant Laboratories, Godawari-3, Lalitpur, Nepal, by referring the deposited plant specimen.

5.2. Extraction and isolation

The fresh A. helfeianara rhizome were cleaned using distilled water, reduced its size using plant cutter, and shade dried for one week to remove moisture content. Successive extraction was done using the methodology of previous research with slight modifications [16]. A. helfeirana rhizome (100 g) was subjected to successive extraction using 70% methanol as solvent in the ratio of 1:10 w/v at 55°C for 2 hours followed by room temperature for 22 hours, and 70% methanol at room temperature for 24 hours. Extracts were filtered using a thick cotton bed and combined to evaporate under reduced pressure at 55°C using rotary evaporator (Biobase RE-2000B, German). The concentrated extracts so obtained after evaporation were poured in beaker, followed by complete drying in vacuum desiccators. All the dried extracts were weighted and stored at 4°C until further use. Extractive yield was estimated as:

% Extractive yield = (weight of dry extract / initial weight of dry sample) × 100

The yield obtained from A. helferiana was 22.81% w/w.

5.3. FT-IR screening

FT-IR provides the insight of functional group present in sample. The department of central instrumental analysis, Nargund College of Pharmacy, Bengaluru, India provided the space and facility for spectral analysis. The IR spectra of methanolic extract was recorded on a FT-IR (Model Shimadzu 8700) in the range of 400–4000 cm-1 by KBr pellet method [56].

5.4. LC-MS profiling

In the process of conducting Liquid Chromatography-Mass Spectrometry (LC-MS) analysis of a plant extract in a sophisticated instrumental laboratory, a series of sequential steps were followed. We performed LC/MS in the sophisticated analytical instrumentation facility, Honeychem pharma research pvt ltd, Bangalore, India. The liquid chromatographic system was UPLC Acquity H class series system where separations were achieved on a WATERS XBridge (50 X 4.6mm 3.5μ), C18 column. The mobile phase consisted of 0.1% formic acid in water (A) and 0.1% formic acid in Acetonitrile HPLC grade (B) at a flow rate of 1.2 mL/min. The analysis was performed using the gradient elution & the condition applied were represented in Tables 1S and 2S in S1 File.

Each extract sample was analysed in positive mode. Identification of secondary metabolites in the extracts of A. helferiana was exclusively based on LC retention time and high- resolution mass spectra. Moreover, the estimation of the elemental composition of ions was based on registered MS m/z values. MS modes were performed with Triple Quadrupole (QqQ) MS/MS analysers in the positive mode [57]. Data, including mass spectra and retention times, were acquired from the mass spectrometer and subsequently analyzed using MassLynxV4.1SCN805 software. Compound identification was performed by comparing mass spectra and retention times with reference standards, published data, and various databases web server.

5.5. Molecular docking protocol

5.5.1. Selection of ligand and protein

In this molecular docking study, the protein target selected was human peroxisome proliferator-activated receptors (PPAR-δ), specifically in complex with the agonist AZ 242 (PDBID: 1I7G) [58]. PPAR-δ is crucial in the pathophysiology of HCC along with the role in metabolic process [59]. This is the novel and most promising receptor for the development of anti-cancer agents. Various clinical observation reported that, the epidermal growth factor receptor (EGRF) is suspectable to develop resistance against drugs [60]. But, PPARs are ligand-activated transcription factors that are part of the nuclear hormone receptor superfamily, playing crucial roles in regulating energy balance, cell differentiation, proliferation, apoptosis, and inflammation. Initial studies connected PPARs to the development of cancer, and currently, PPARs are associated with various solid organ cancers, including those of the breast, ovary, prostate, bladder, stomach, colon, and lungs. Therefore, we choose PPAR- δ for our research as receptor [61, 62]. The 3D structure of the protein was obtained from the Protein Data Bank (PDB) (https://www.rcsb.org/) and subjected to purification using BIOVIA Discovery Studio 2021 to eliminate water molecules, heteroatoms, and undesired ligands. Subsequently, the protein structure underwent optimization, including energy minimization, to prepare it for the docking protocol. The protein was selected on the basis of biological relevance, availability of a known 3D structure (resolution = 2.20 Å), and relevance to the research question (non-mutated). The chosen protein was further optimized for docking studies, ensuring its suitability for the investigation. Simultaneously, 17 phytoconstituents derived from LC-MS analysis of A. helferiana were chosen as ligands (Fig 10). Their 3D structures were retrieved from the Indian Medicinal Plants, Phytochemistry and Therapeutics 2.0 (IMPPAT 2.0) database (https://cb.imsc.res.in/imppat/) [63] in simple dimension file (SDF) format, followed by energy minimization (MMFF 96 force field), chirality optimization, and conversion into PDBQT format from Open babel 2.4.1 software [64].

Fig 10. 2D structure of phytoconstituents along with their name and code (B1 toB17).

Fig 10

5.5.2. Validation of protein

The PROCHECK tool (http://saves.mbi.ucla.edu/) [65] was used to determine the accuracy and quality of the selected PPAR-δ protein. Moreover, the physiochemical properties of selected protein were determined by Expasy-ProtParam web server (https://web.expasy.org/protparam/) [66].

5.5.3. Grid box generation and docking process

The molecular docking simulation was conducted using AutoDock Vina1.5.7 software [67], wherein the prepared PPAR-δ protein and 17 phytoconstituents (ligands) structures were loaded, and docking parameters were set, encompassing grid box dimensions, search parameters, and scoring functions. The grid box generation in AutoDock Vina 1.5.7 involves setting up the parameters that define the search space within which the docking simulations will take place. In this case, the default settings for AutoDock Vina 1.5.7 were utilized, where the grid box axis and dimensions were automatically selected. The default parameters for the grid box were as follows: x-axis = 30.857 Å, y-axis = 29.068 Å, and z-axis = 30.740 Å, and the overall size of the grid box was set to 40 Å. The specified dimensions (30.857 Å, 29.068 Å, and 30.740 Å) define the lengths of the grid box along each axis, while the overall size of 40 Å suggests the cubic shape of the grid box. This grid box serves as the exploration space for the ligand to dock into the binding site of the protein [68]. The dimensions and size of the grid box are crucial parameters, influencing the accuracy and efficiency of the docking simulation. AutoDock’s default settings, as described, were applied in this procedure to ensure a balanced and appropriate exploration of the protein’s active site by the ligands during the docking studies. The software explored potential binding conformations, predicting the binding affinity of each ligand with the protein. Post-simulation, the results were meticulously analyzed, focusing on binding affinity and the mode of interaction between ligands and the protein. The evaluation was carried out with emphasis on docking scores and interaction patterns to identify the most promising ligands [69].

5.5.4. Results visualization

The visualization of the docked complex was accomplished using BIOVIA Discovery Studio Visualizer 2021 software, facilitating the analysis of binding modes, hydrogen bonding, and other crucial interactions between phytoconstituents (ligands) and the PPAR-δ protein. The results obtained from this study were used in further experiments to validate and explore the biological significance of the predicted interactions [70].

5.5.5. Docking results validation

To validate docking results using PyMol 2.5.2 software, the procedure involved loading both the co-crystal native ligand and docked complex structures, superimposing the structures for alignment, and calculating the root mean square deviation (RMSD) between the docked ligand and the reference co-crystal ligand. The PyMol 2.5.2 command for RMSD calculation was used to obtain quantitative information on structural similarity. The results were visualized in PyMol 2.5.2, where a lower RMSD indicates better alignment and more accurate prediction. Typically, an RMSD below 2 Å is considered good, while values above 4 Å may suggest less reliable predictions (Fig 1S in S1 File). The entire analysis, including specific binding interactions and spatial orientation, was checked for comprehensive validation of the molecular docking results [71].

5.6. ADME prediction

To determine absorption, distribution, metabolism, and excretion (ADME) properties, we employed the ADMETlab 2.0 server (https://admetmesh.scbdd.com/) [72], a computational platform for predicting drug-like properties. The procedure involved accessing the ADMETlab 2.0 server through a web browser. Once on the platform, we input the simplified molecular-input line-entry system (SMILES) notation of the compound of interest. The server employed various algorithms and multi-task graph attention framework along with batch computation module to predict key ADME properties. The absorption prediction assesses factors like gastrointestinal absorption, partition coefficient and water solubility. Distribution predictions consider factors influencing the compound’s distribution within the body. Metabolism predictions evaluate the likelihood of metabolism by cytochrome P450 enzymes. Excretion predictions focus on renal and non-renal clearance [73].

5.6.1. Passive membrane permeability and translocation pathways

For the purpose of performing quantitative analysis and visualizing the passive translocation of bioactive compounds across lipid membranes, the PerMM web server (https://permm.phar.umich.edu/) [74] was set up. The server is a physics-based web application that calculates membrane binding energies and permeability coefficients of various compounds across different types of membranes such as phospholipid bilayers, parallel artificial membrane permeability assay-double sink (PAMPA-DS), blood-brain barrier (BBB), and CaCO2/MDCK (Madin–Darby canine kidney cell line) cell membranes. The process visualizes the movement of a substance across a lipid bilayer by showing its translational and rotational locations, as well as the changes in solvation energy [75].

5.7. In-vitro cell line study

Each well of a 96-well microtiter plate was filled with 200 μL of a medium (HepG2 Human liver cancer cell line) containing roughly 10 thousand cells. Additionally, 200 μL of five different concentrations of test materials were added to each well. 5-Fluorouracil was used as the standard. After adding 10% MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) reagent to each well to reach a concentration of 0.5 mg/mL, the samples were incubated for 3 hours. The culture media was removed without disturbing the formed crystal. The formazan was subsequently dissolved by adding 100 μL of DMSO (a solubilization solution) and gently agitating it in a gyrator shaker. The time of contact used between extract sample with the cell line was 24 hours. The measurement of absorbance was conducted at wavelengths of 570 nm and 630 nm [76].

Supporting information

S1 File

(DOCX)

Acknowledgments

We thank Honeychem pharma research Pvt. Ltd., Bangalore, India, Nargund College of Pharmacy and Pokhara University for providing the site of instrumental analysis. We also thank CellKraft Biotech Pvt. Ltd, Banglore, India for providing cytotoxic activity.

Data Availability

All the date used in manuscript are provided in within manuscript.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Gu X. and Manautou J. E., “Molecular mechanisms underlying chemical liver injury,” Expert Rev. Mol. Med., vol. 14, no. e4, p. e4, Feb. 2012, doi: 10.1017/S1462399411002110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Shrestha G., Thakur R. K., Singh R., Mulmi R., Shrestha A., and Pradhan P. M. S., “Cancer burden in Nepal, 1990–2017: An analysis of the Global Burden of Disease study,” PLoS One, vol. 16, no. 8 August, pp. 1–25, 2021, doi: 10.1371/journal.pone.0255499 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Shrestha A., “Liver Cancer in Nepal,” Euroasian J. Hepato-Gastroenterology, vol. 8, no. 1, pp. 63–65, 2018, doi: 10.5005/jp-journals-10018-1261 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Habtemariam S. and Lentini G., “Plant-derived anticancer agents: Lessons from the pharmacology of geniposide and its aglycone, genipin,” Biomedicines, vol. 6, no. 39, pp. 1–28, 2018, doi: 10.3390/biomedicines6020039 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Ali Abdalla Y. O. et al. , “Natural Products for Cancer Therapy: A Review of Their Mechanism of Actions and Toxicity in the Past Decade,” J. Trop. Med., vol. 2022, pp. 1–20, 2022, doi: 10.1155/2022/5794350 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Yang J. D., Hainaut P., Gores G. J., Amadou A., Plymoth A., and Roberts L. R., “A global view of hepatocellular carcinoma: trends, risk, prevention and management,” Nat. Rev. Gastroenterol. Hepatol., vol. 16, no. 10, pp. 589–604, Oct. 2019, doi: 10.1038/s41575-019-0186-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Llovet J. M. et al. , “Hepatocellular carcinoma,” Nat. Rev. Dis. Prim., vol. 7, no. 1, pp. 1–28, 2021, doi: 10.1038/s41572-020-00240-3 [DOI] [PubMed] [Google Scholar]
  • 8.Philips C. A., Rajesh S., Nair D. C., Ahamed R., Abduljaleel J. K., and Augustine P., “Hepatocellular Carcinoma in 2021: An Exhaustive Update,” Cureus, vol. 13, no. 11, 2021, doi: 10.7759/cureus.19274 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.V Sashidhara K., Rosaiah J. N., and Medicinal, “Various Dereplication Strategies Using LC-MS for Rapid Natural Product Lead Identification and Drug Discovery Koneni,” Nat. Prod. Commun., vol. 2, no. 2, pp. 193–202, 2007. [Google Scholar]
  • 10.Seo C. S. and Lee M. Y., “HPLC-PDA and LC-MS/MS analysis for the simultaneous quantification of the 14 marker components in Sojadodamgangki-Tang,” Appl. Sci., vol. 10, no. 8, 2020, doi: 10.3390/APP10082804 [DOI] [Google Scholar]
  • 11.Patel K., Patel J., Patel M., Rajput G., and Patel H., “Introduction to hyphenated techniques and their applications in pharmacy,” Pharm. Methods, vol. 1, no. 1, p. 2, 2010, doi: 10.4103/2229-4708.72222 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Verma N., “Advances and trends in analytical techniques in natural product research: Challenges and future perspective,” Indian J. Nat. Prod. Resour., vol. 12, no. 4, pp. 506–526, 2021, doi: 10.56042/ijnpr.v12i4.33328 [DOI] [Google Scholar]
  • 13.Romano J. D. and Tatonetti N. P., “Informatics and computational methods in natural product drug discovery: A review and perspectives,” Front. Genet., vol. 10, no. APR, pp. 1–16, 2019, doi: 10.3389/fgene.2019.00368 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Burle S. S., Gupta K. R., Jibhkate Y. J., Hemke A. T., and Umekar M. J., “Insights into molecular docking: A comprehensive view,” Int. J. Pharm. Chem. Anal., vol. 10, no. 3, pp. 175–184, 2023, doi: 10.18231/j.ijpca.2023.030 [DOI] [Google Scholar]
  • 15.Shen J. et al. , “Virtual Screening on Natural Products for Discovering Active Compounds and Target Information,” Curr. Med. Chem., vol. 10, no. 21, pp. 2327–2342, 2005, doi: 10.2174/0929867033456729 [DOI] [PubMed] [Google Scholar]
  • 16.Lamichhane R., Pandeya P., Lee K.-H., Kim S.-G., Kandel D., and Jung H.-J., “Angiopteris helferiana, a fern with great potential medicinal value: Antiadipogenic, anti-inflammatory, and anti-diabetic activity,” Pharmacogn. Mag., vol. 15, no. 63, p. 423, 2019, doi: 10.4103/pm.pm_430_18 [DOI] [Google Scholar]
  • 17.Silambarasan R. and Ayyanar M., “An ethnobotanical study of medicinal plants in Palamalai region of Eastern Ghats, India,” J. Ethnopharmacol., vol. 172, no. 8, pp. 162–178, Aug. 2015, doi: 10.1016/j.jep.2015.05.046 [DOI] [PubMed] [Google Scholar]
  • 18.Pandey B., Baral R., Kaundinnyayana A., and Panta S., “Promising hepatoprotective agents from the natural sources: a study of scientific evidence,” Egypt. Liver J., vol. 13, no. 1, 2023, doi: 10.1186/s43066-023-00248-w [DOI] [Google Scholar]
  • 19.Komala I., Sitorus S., Dewi F. R., Nurmeilis N., and Hendarmin L. A., “Cytotoxic Activity of the Indonesian Fern Angiopteris angustifolia C. Presl and Liverwort Mastigophora diclados (Birs. ex Web) Nees Against Breast Cancer Cell Lines (MCF-7),” J. Kim. Val., vol. 8, no. 1, pp. 79–84, 2022, doi: 10.15408/jkv.v8i1.22645 [DOI] [Google Scholar]
  • 20.Sara S. C. and Ruby R. G. D., “In Vitro Antiproliferative Effect of Angiopteris evecta (G. Forst.) Hoffm. Extracts against Cultured HT-29 Colon Cancer Cells,” in Ferns, vol. 36, no. 3, Singapore: Springer Nature Singapore, 2022, pp. 537–551. [Google Scholar]
  • 21.Nur S. et al. , “Evaluation of antioxidant and cytotoxic effect against cancer cells line of Angiopteris ferox Copel tuber and its compounds by LC-MS analysis,” J. Appl. Pharm. Sci., vol. 11, no. 8, pp. 54–61, 2021, doi: 10.7324/JAPS.2021.110808 [DOI] [Google Scholar]
  • 22.Aisyah A. et al. , “In Vitro antioxidant and cytotoxic evaluation of ethyl acetate fraction of Angiopteris ferox Copel tuber against HTB lung cancer cell,” Egypt. J. Chem., vol. 275, no. 36, pp. 0–0, Mar. 2022, doi: 10.21608/ejchem.2022.91843.4364 [DOI] [Google Scholar]
  • 23.Ramírez-Hernández A., Aguilar-Flores C., and Aparicio-Saguilán A., “Fingerprint analysis of FTIR spectra of polymers containing vinyl acetate,” DYNA, vol. 86, no. 209, pp. 198–205, Apr. 2019, doi: 10.15446/dyna.v86n209.77513 [DOI] [Google Scholar]
  • 24.Lamichhane R., Pandeya P. R., Lee K. H., Kim S. G., Devkota H. P., and Jung H. J., “Anti‐Adipogenic and Anti‐inflammatory activities of (−)‐epi‐Osmundalactone and angiopteroside from angiopteris helferiana C.Presl,” Molecules, vol. 25, no. 6, 2020, doi: 10.3390/molecules25061337 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Thomson M. I., Nichol G. S., and Lawrence A. L., “Total Synthesis of (−)-Angiopterlactone B,” Org. Lett., vol. 19, no. 9, pp. 2199–2201, 2017, doi: 10.1021/acs.orglett.7b00929 [DOI] [PubMed] [Google Scholar]
  • 26.Tine Y., Yang Y., Renucci F., Costa J., Wélé A., and Paolini J., “LC-MS/MS analysis of flavonoid compounds from Zanthoxylum zanthoxyloides extracts and their antioxidant activities,” Nat. Prod. Commun., vol. 12, no. 12, pp. 1865–1868, 2017, doi: 10.1177/1934578x1701201213 [DOI] [Google Scholar]
  • 27.Kaur J., Dhiman V., Bhadada S., Katare O. P., and Ghoshal G., “LC/MS guided identification of metabolites of different extracts of Cissus quadrangularis,” Food Chem. Adv., vol. 1, no. August, p. 100084, 2022, doi: 10.1016/j.focha.2022.100084 [DOI] [Google Scholar]
  • 28.Staszków A., Swarcewicz B., Banasiak J., Muth D., Jasiński M., and Stobiecki M., “LC/MS profiling of flavonoid glycoconjugates isolated from hairy roots, suspension root cell cultures and seedling roots of Medicago truncatula,” Metabolomics, vol. 7, no. 4, pp. 604–613, 2011, doi: 10.1007/s11306-011-0287-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Ali A. et al. , “Network Pharmacology Integrated Molecular Docking and Dynamics to Elucidate Saffron Compounds Targeting Human COX-2 Protein,” Med., vol. 59, no. 12, pp. 1–30, 2023, doi: 10.3390/medicina59122058 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Walker John M., The Proteomics Protocols Handbook. Totowa, NJ: Humana Press, 2005. [Google Scholar]
  • 31.Bastos M., dos Santos M. H., and Camps I., “Molecular docking vs structure optimization,” J. Org. Chem. Res., vol. 1, no. 1, pp. 1–9, May 2013, doi: 10.12785/jocr/010101 [DOI] [Google Scholar]
  • 32.Mohanty M. and Mohanty P. S., “Molecular docking in organic, inorganic, and hybrid systems: a tutorial review,” Monatshefte fur Chemie, vol. 154, no. 7, pp. 683–707, 2023, doi: 10.1007/s00706-023-03076-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Agu P. C. et al. , “Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management,” Sci. Rep., vol. 13, no. 1, pp. 1–18, 2023, doi: 10.1038/s41598-023-40160-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Shah M., Patel M., Shah M., Patel M., and Prajapati M., “Computational transformation in drug discovery: A comprehensive study on molecular docking and quantitative structure activity relationship (QSAR),” Intell. Pharm., vol. 2024, no. 4, pp. 1–30, 2024, doi: 10.1016/j.ipha.2024.03.001 [DOI] [Google Scholar]
  • 35.Li X. H., Zou H. J., Wu A. H., Ye Y. L., and Shen J. H., “Structure-based drug design of a novel family of chalcones as PPARα agonists: Virtual screening, synthesis, and biological activities in vitro,” Acta Pharmacol. Sin., vol. 28, no. 12, pp. 2040–2052, 2007, doi: 10.1111/j.1745-7254.2007.00670.x [DOI] [PubMed] [Google Scholar]
  • 36.Wang C. Y. et al. , “Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer,” Int. J. Med. Sci., vol. 18, no. 1, pp. 256–269, 2021, doi: 10.7150/ijms.48123 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Sun J., Yu L., Qu X., and Huang T., “The role of peroxisome proliferator-activated receptors in the tumor microenvironment, tumor cell metabolism, and anticancer therapy,” Front. Pharmacol., vol. 14, no. May, pp. 1–21, 2023, doi: 10.3389/fphar.2023.1184794 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Enayati A., Ghojoghnejad M., Roufogalis B. D., Maollem S. A., and Sahebkar A., “Impact of Phytochemicals on PPAR Receptors: Implications for Disease Treatments,” PPAR Res., vol. 2022, 2022, doi: 10.1155/2022/4714914 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Murugan Sreedevi S. et al. , “Molecular Docking approach on the effect of Site- Selective and Site-Specific Drugs on the Molecular Interactions of Human Serum Albumin (HSA) -Acridinedione dye complex,” Arab. J. Chem., vol. 16, no. 5, p. 104701, 2023, doi: 10.1016/j.arabjc.2023.104701 [DOI] [Google Scholar]
  • 40.Dong J. et al. , “Admetlab: A platform for systematic ADMET evaluation based on a comprehensively collected ADMET database,” J. Cheminform., vol. 10, no. 1, pp. 1–11, 2018, doi: 10.1186/s13321-018-0283-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Shaikh R., O’Brien D. P., Croker D. M., and Walker G. M., “The development of a pharmaceutical oral solid dosage forms,” 2018, pp. 27–65. [Google Scholar]
  • 42.Wu Z., Lei T., Shen C., Wang Z., Cao D., and Hou T., “ADMET Evaluation in Drug Discovery. 19. Reliable Prediction of Human Cytochrome P450 Inhibition Using Artificial Intelligence Approaches,” J. Chem. Inf. Model., vol. 59, no. 11, pp. 4587–4601, Nov. 2019, doi: 10.1021/acs.jcim.9b00801 [DOI] [PubMed] [Google Scholar]
  • 43.Lipinski C. A., Lombardo F., Dominy B. W., and Feeney P. J., “Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings,” Adv. Drug Deliv. Rev., vol. 23, no. 1–3, pp. 3–25, Dec. 1997, doi: 10.1016/j.addr.2012.09.019 [DOI] [PubMed] [Google Scholar]
  • 44.Kralj S., Jukič M., and Bren U., “Molecular Filters in Medicinal Chemistry,” Encyclopedia, vol. 3, no. 2, pp. 501–511, 2023, doi: 10.3390/encyclopedia3020035 [DOI] [Google Scholar]
  • 45.Zhang M. Q. and Wilkinson B., “Drug discovery beyond the ‘rule-of-five,’” Curr. Opin. Biotechnol., vol. 18, no. 6, pp. 478–488, 2007, doi: 10.1016/j.copbio.2007.10.005 [DOI] [PubMed] [Google Scholar]
  • 46.Doak B. C. and Kihlberg J., “Drug discovery beyond the rule of 5—Opportunities and challenges,” Expert Opin. Drug Discov., vol. 12, no. 2, pp. 115–119, 2017, doi: 10.1080/17460441.2017.1264385 [DOI] [PubMed] [Google Scholar]
  • 47.Egbert M., Whitty A., Keserü G. M., and Vajda S., “Why Some Targets Benefit from beyond Rule of Five Drugs,” J. Med. Chem., vol. 62, no. 22, pp. 10005–10025, 2019, doi: 10.1021/acs.jmedchem.8b01732 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Biedermann F., Ghale G., Hennig A., and Nau W. M., “Fluorescent artificial receptor-based membrane assay (FARMA) for spatiotemporally resolved monitoring of biomembrane permeability,” Commun. Biol., vol. 3, no. 1, pp. 1–10, 2020, doi: 10.1038/s42003-020-1108-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Mazzanti L. and Ha-Duong T., “Understanding Passive Membrane Permeation of Peptides: Physical Models and Sampling Methods Compared,” Int. J. Mol. Sci., vol. 24, no. 5, 2023, doi: 10.3390/ijms24055021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Clemente C. M., Onnainty R., Usseglio N., Granero G. E., and Ravetti S., “Preformulation Studies of Novel Menthol Prodrugs with Antiparasitic Activity: Chemical Stability, In Silico, and In Vitro Permeability Assays,” Drugs Drug Candidates, vol. 2, no. 3, pp. 770–780, 2023, doi: 10.3390/ddc2030038 [DOI] [Google Scholar]
  • 51.Ungureanu A. R. et al. , “Cytotoxicity Analysis and In Silico Studies of Three Plant Extracts with Potential Application in Treatment of Endothelial Dysfunction,” Pharmaceutics, vol. 15, no. 8, pp. 1–23, 2023. doi: 10.3390/pharmaceutics15082125 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Clemente C. M., Robledo S. M., and Ravetti S., “Menthol carbonates as potent antiparasitic agents: synthesis and in vitro studies along with computer-aided approaches,” BMC Complement. Med. Ther., vol. 22, no. 1, p. 156, Dec. 2022, doi: 10.1186/s12906-022-03636-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.He Y. et al. , “The changing 50% inhibitory concentration (IC50) of cisplatin: A pilot study on the artifacts of the MTT assay and the precise measurement of density-dependent chemoresistance in ovarian cancer,” Oncotarget, vol. 7, no. 43, pp. 70803–70821, 2016, doi: 10.18632/oncotarget.12223 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Awad S. M., Fathalla O. A., Wietrzyk J., Milczarek M., Soliman A. M., and Mohamed M. S., “Synthesis of new pyrimidine derivatives and their antiproliferative activity against selected human cancer cell lines,” Res. Chem. Intermed., vol. 41, no. 3, pp. 1789–1801, 2015, doi: 10.1007/s11164-013-1312-z [DOI] [Google Scholar]
  • 55.EL-HALLOUTY S., BATAWI A., SHAFI M., RASHWAN E., ELHAWARY E., and ABDELAAL N., “Cytotoxicity of Five Plant Extracts Against Different Human Cancer Cell Lines and Their Molecular Mechanism,” Asian J. Pharm. Clin. Res., no. October, pp. 194–198, 2020, doi: 10.22159/ajpcr.2020.v13i10.38698 [DOI] [Google Scholar]
  • 56.Shepel D., Goreacioc T., Lupascu T., Filippov M., and Rusu M., “Method of infrared spectra registration of activated carbons in potassium bromides pellets,” Chem. J. Mold., vol. 10, no. 1, pp. 113–115, 2015. [Google Scholar]
  • 57.Abdulhafiz F. et al. , “LC–TOF-MS/MS and GC-MS based phytochemical profiling and evaluation of wound healing activity of Oroxylum Indicum (L.) Kurz (Beka),” Front. Pharmacol., vol. 13, no. November, pp. 1–14, 2022, doi: 10.3389/fphar.2022.1050453 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Cronet P. et al. , “Structure of the PPAR␣ and -␥ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family,” Structure, vol. 9, no. 01, pp. 699–706, 2001. [DOI] [PubMed] [Google Scholar]
  • 59.Shi Q., Zeng Y., Xue C., Chu Q., Yuan X., and Li L., “Development of a promising PPAR signaling pathway-related prognostic prediction model for hepatocellular carcinoma,” Sci. Rep., vol. 14, no. 1, pp. 1–14, 2024, doi: 10.1038/s41598-024-55086-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Spiro S. G. and Porter J. C., “Lung cancer—Where are we today? Current advances in staging and nonsurgical treatment,” Am. J. Respir. Crit. Care Med., vol. 166, no. 9, pp. 1166–1196, 2002, doi: 10.1164/rccm.200202-070SO [DOI] [PubMed] [Google Scholar]
  • 61.Roman J., “Moving away from PPARs—EGFR signaling and the anti-cancer effects of thiazolinedinediones,” Cell Res., vol. 19, no. 6, pp. 669–671, 2009, doi: 10.1038/cr.2009.62 [DOI] [PubMed] [Google Scholar]
  • 62.Zhao Y., Tan H., Zhang X., and Zhu J., “Roles of peroxisome proliferator-activated receptors in hepatocellular carcinoma,” Journal of Cellular and Molecular Medicine, vol. 28, no. 5. pp. 1–12, Mar. 20, 2024, doi: 10.1111/jcmm.18042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Vivek-Ananth R. P., Mohanraj K., Sahoo A. K., and Samal A., “IMPPAT 2.0: An Enhanced and Expanded Phytochemical Atlas of Indian Medicinal Plants,” ACS Omega, vol. 8, no. 9, pp. 8827–8845, 2023, doi: 10.1021/acsomega.3c00156 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.O’Boyle N. M., Banck M., James C. A., Morley C., Vandermeersch T., and Hutchison G. R., “Open Babel: An open chemical toolbox,” J. Cheminform., vol. 3, no. 33, pp. 1–14, 2011, [Online]. Available: https://jcheminf.biomedcentral.com/track/pdf/ doi: 10.1186/1758-2946-3-33 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Laskowski R. A., MacArthur M. W., Moss D. S., and Thornton J. M., “PROCHECK: a program to check the stereochemical quality of protein structures,” J. Appl. Crystallogr., vol. 26, no. 2, pp. 283–291, Apr. 1993, doi: 10.1107/S0021889892009944 [DOI] [Google Scholar]
  • 66.Thapa S., Nargund S. L., and Biradar M. S., “Molecular Design and In-Silico Analysis of Trisubstituted Benzimidazole Derivatives as Ftsz Inhibitor,” J. Chem., vol. 2023, no. 7, pp. 1–9, Mar. 2023, doi: 10.1155/2023/9307613 [DOI] [Google Scholar]
  • 67.Trott O. and Olson A. J., “AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading,” J. Comput. Chem., vol. 31, no. 2, pp. 455–461, 2009, doi: 10.1002/jcc.21334 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Thapa S., Nargund S. L., Biradar M. S., Banerjee J., and Karati D., “In-silico investigation and drug likeliness studies of benzimidazole congeners: The new face of innovation,” Informatics Med. Unlocked, vol. 38, no. January, pp. 1–22, 2023, doi: 10.1016/j.imu.2023.101213 [DOI] [Google Scholar]
  • 69.Thapa S. et al. , “Synthesis, Molecular Docking, Molecular Dynamic Simulation Studies, and Antitubercular Activity Evaluation of Substituted Benzimidazole Derivatives,” Adv. Pharmacol. Pharm. Sci., vol. 2024, no. 9, pp. 1–14, Mar. 2024, doi: 10.1155/2024/9986613 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Pant L., Thapa S., Dahal B., Khadka R., and Biradar M. S., “In Silico and In Vitro Studies of Antibacterial Activity of Cow Urine Distillate (CUD),” Evidence-Based Complement. Altern. Med., vol. 2024, pp. 1–10, Jan. 2024, doi: 10.1155/2024/1904763 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Thapa S., Biradar M. S., Banerjee J., and Karati D., “In-silico Approach for Predicting the Inhibitory Effect of Home Remedies on Severe Acute Respiratory Syndrome Coronavirus-2,” Makara J. Sci., vol. 27, no. 3, pp. 194–207, 2023, doi: 10.7454/mss.v27i3.1609 [DOI] [Google Scholar]
  • 72.Xiong G. et al. , “ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties,” Nucleic Acids Res., vol. 49, no. 1, pp. 5–14, Jul. 2021, doi: 10.1093/nar/gkab255 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Gote S., Thapa S., Dubey S., Nargund S. L., and Biradar M. S., “Computational investigation of quinazoline derivatives as Keap1 inhibitors for Alzheimer’s disease,” Informatics Med. Unlocked, vol. 41, no. July, pp. 1–13, 2023, doi: 10.1016/j.imu.2023.101334 [DOI] [Google Scholar]
  • 74.Lomize A. L. et al. , “PerMM: A Web Tool and Database for Analysis of Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules,” J. Chem. Inf. Model., vol. 59, no. 7, pp. 3094–3099, 2019, doi: 10.1021/acs.jcim.9b00225 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Lomize A. L. and Pogozheva I. D., “Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules,” J. Chem. Inf. Model., vol. 59, no. 7, pp. 3198–3213, 2019, doi: 10.1021/acs.jcim.9b00224 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Biradar M. S., Nargund S. L., and Thapa S., “Synthesis and Cytotoxicity Assay of Aniline Substituted Thienopyrimidines for Anti-Colorectal Cancer Activity,” Results Chem., vol. 5, no. April, p. 100926, 2023, doi: 10.1016/j.rechem.2023.100926 [DOI] [Google Scholar]

Decision Letter 0

Ghulam Mustafa

26 Jun 2024

PONE-D-24-20408LC-MS Profiling and Cytotoxic Activity of Angiopteris helferiana Against HepG2 Cell Line: Molecular Insight to Investigate Anticancer AgentPLOS ONE

Dear Dr. Thapa,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Aug 10 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Ghulam Mustafa, PhD

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Methods section, please provide additional information regarding the permits you obtained for the work. Please ensure you have included the full name of the authority that approved the field site access and, if no permits were required, a brief statement explaining why.

3. Please note that PLOS ONE has specific guidelines on code sharing for submissions in which author-generated code underpins the findings in the manuscript. In these cases, we expect all author-generated code to be made available without restrictions upon publication of the work. Please review our guidelines at https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

Reviewer #3: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: I Don't Know

Reviewer #3: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The work is oriented towards the anticancer effect of exttract of Angiopteris helferiana (A. helferiana) C. Presl is a large 88 fleshy fern. However it is traditionaly used in many diseases, I have to reaise a question on what base the authors selected the anticancer against one line of cells? is it indicative results to get the results against HepG2 Cell only?Also, the activity due to the extract however the authors recorded the activity is due to very well known compounds like quercetion where there are a lot of reports regardong this compound as anticancer and up till now not used, So, extensive study on these componds is consider a waste of time and effeort.

I think the authors have to work in purified fraction preceded with activity guided fractionation to get standartized active simple fraction could be applied in pharmaceutical market.

-table 1- column 10 it is coumarin not falavonoid because coumarin is 9 carbon mostly and flavonoid is 15 carbon

Please revise the content vey well.

discussion need more information to get the conclusion in right way.

Reviewer #2: 1. the authors must compare the effect of cyto-toxic on normal cell line like RPE1 or BJ1

2. the IC 50 of 5-fluorouracil is too high

3. the time of contact between extract or drug with the cell is not mentioned

Reviewer #3: . PLOS ONE

LC-MS Profiling and Cytotoxic Activity of Angiopteris helferiana Against HepG2 Cell Line: Molecular Insight to Investigate Anticancer Agent

.

Reviewer comments:

Results and discussion: lines111/112: peak at 2927cm-1 confirms the presence of phenolic group? The band 2927cm-1 is attributed the aliphatic C-H stretching, revise the value again.

Lines 116/117: 1392 cm-1and 1269 cm-1indicates the involvement of stretching vibration of different aliphatic alkyl groups.?? The given 1392 and 1269cm-1 values are not due to C-H stretching? Please change the assignment values again.

2.4 Molecular Docking: line: 174

A. helferiana extract) when bound to a target molecule (human PPAR-δ receptor).

Why did the author choose Humn PPAR-δ as the enzyme-protein target for A.helferiana more than alternative binding targets? Like EGFR and VEGFR? HDACs, etc. Provide reasonable explanations.

Furthermore, did the author do docking binding studies with other targets than PPAR-δ, and verified that PPAR-δ is the best for interaction according to binding free energy (Kcal/mol) and RMSD (Ẩ)?

The author provided a thorough description of the interactions between the secondary metabolites and the target protein, including the sorts of interactions.

2.7. Analysis of passive membrane permeability and translocation pathways, line:328: compounds (Menthol carbonates) described by Mollazadeh et al, cite reference number for this author.

2.8.HepG2 cell line study

Lines: 338-340 :This screening was conducted to validate the in-silico molecular docking results. Interestingly, the extract showed the significant cytotoxic activity having IC50 value of 236.93 μg/ml (Table 7 and Figure 9). This result indicates the potential activity of extract towards HepG2 Human liver cancer cell line.>>> The IC50 value of 236.93µg/ML for the extract is low-moderate and not notable

NOTE: An extract is defined to be highly active if it has IC50 < 10 µg/ml, active when the IC50 is between 10 µg/ml and 100 µg/ml, moderately active if the IC50 is between 100µg/ml and 500µg/ml, and low activity if the IC50 is ˃ 500 µg/ml

Bahadori, M H., Azari, Z., Zaminy, A., Dabirian, S., Mehrdad, S M., & Kondori, B J. (2021, March 31). Anti-proliferative and apoptotic effects of hull-less pumpkin extract on human papillary thyroid carcinoma cell line. , 54(1), 104-111. https://doi.org/10.5115/acb.20.22.

The author should test the cytotoxicity of the extract on a normal cell line, and then calculate the selectivity index (SI) (IC50 normal cells / IC50 cancer cells).

Line: 342: The reference (35): The drug 5-Flurouracil, IC50= (435.59 μg/ml,(35)), and Table 7:>>> This reference specifies the IC50 against the HCT116 cell line,?? NOT against the HEPG2 cancer cell line; correct the statement and conclusion, which do not match the HEPG2 cell line that you employed.

Reference: must be written as references.

** It was obvious from the 17 phytoconstituents that each secondary metabolite was docked with the target enzyme, although the IC50 was measured collectively for the entire extract, due to the difficulty in isolating each constituent alone.

In vitro evaluation for secondary metabolites requires particular tests, such as cell cycle arrest, apoptosis, and enzyme assays. However, the difficulty of separating individual phytoconstituents limits the study.

……………………………………………END………………………………………………………

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Prof. Abdel Nasser B. Singab, Ain Shams University, Faculty of Pharmacy, Dept. of Pharmacognosy, Founder and supervispor of Center of Drug Discovery Research and Develpment

Reviewer #2: No

Reviewer #3: Yes: Ammar A. Razzak Mahmood

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Manuscript.docx

pone.0309797.s002.docx (134.6KB, docx)
PLoS One. 2024 Dec 31;19(12):e0309797. doi: 10.1371/journal.pone.0309797.r002

Author response to Decision Letter 0


1 Jul 2024

We would like to thank reviewer for their valuable insight and comments. we have provided the word file stating point-wise response the reviewers.

we have revised the manuscript as stated by editor and added the information asked by journal.

Attachment

Submitted filename: Response to Reviwers.docx

pone.0309797.s003.docx (29.2KB, docx)

Decision Letter 1

Ghulam Mustafa

20 Aug 2024

LC-MS Profiling and Cytotoxic Activity of Angiopteris helferiana Against HepG2 Cell Line: Molecular Insight to Investigate Anticancer Agent

PONE-D-24-20408R1

Dear Dr. Thapa,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Ghulam Mustafa, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #3: The author addressed the comments made in the prior contribution.

The compound's docking profile is explored and fully described.

In addition, the IC50 value of 5-FU was adjusted, and the author conducted a thorough comparison with the recovered bioactive compounds.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #3: Yes: Ammar A. Razzak Mahmood

**********

Acceptance letter

Ghulam Mustafa

9 Sep 2024

PONE-D-24-20408R1

PLOS ONE

Dear Dr. Thapa,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Ghulam Mustafa

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File

    (DOCX)

    Attachment

    Submitted filename: Manuscript.docx

    pone.0309797.s002.docx (134.6KB, docx)
    Attachment

    Submitted filename: Response to Reviwers.docx

    pone.0309797.s003.docx (29.2KB, docx)

    Data Availability Statement

    All the date used in manuscript are provided in within manuscript.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES